Trial Profile
Pilot RCT of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Beta-lactamase Producing Enterobacter Spp., Citrobacter Freundii, Morganella Morganii, Providencia Spp. or Serratia Marcescens. in Low-risk Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary) ; Meropenem
- Indications Citrobacter infections; Enterobacter infections; Providencia infections; Serratia infections
- Focus Therapeutic Use
- Acronyms MERINO 2; MERINO II
- 09 May 2023 Status changed from active, no longer recruiting to completed.
- 03 Nov 2020 Planned End Date changed from 1 Sep 2020 to 1 Dec 2020.
- 03 Nov 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2020.